| 吉非替尼的临床应用研究 |
| |
| 引用本文： | 杨同江,王全亮,解李丽,单衍强. 吉非替尼的临床应用研究[J]. 药学研究, 2017, 36(4): 243-245. DOI: 10.13506/j.cnki.jpr.2017.04.015 |
| |
| 作者姓名： | 杨同江 王全亮 解李丽 单衍强 |
| |
| 作者单位： | 齐鲁制药〈海南〉有限公司,海南 海口,570314 |
| |
| 摘 要： | 吉非替尼为靶向性表皮生长因子受体(EGFR)酪氨酸激酶抑制剂,2005年批准进口中国用于治疗局部晚期及或转移性非小细胞肺癌(NSCLC),其疗效好且血液系统不良反应较少,最常见的不良反应为腹泻和皮肤反应.2015年7月13日,美国食品药品监督管理局批准吉非替尼用于转移性非小细胞肺癌靶向性表皮生长因子受体基因突变的患者.本文主要综述了其近年国内外的临床研究进展.
|
| 关 键 词： | 吉非替尼 抗肿瘤 临床研究 |
Clinical application of Gefitinib |
| |
| YANG Tongjiang,WANG Quanliang,XIE Lili and SHAN Yanqiang. Clinical application of Gefitinib[J]. Journal of Pharmaceutical Research, 2017, 36(4): 243-245. DOI: 10.13506/j.cnki.jpr.2017.04.015 |
| |
| Authors: | YANG Tongjiang WANG Quanliang XIE Lili SHAN Yanqiang |
| |
| Affiliation: | Qilu Pharmaceutical Co.,Ltd.,Haikou 570314, China,Qilu Pharmaceutical Co.,Ltd.,Haikou 570314, China,Qilu Pharmaceutical Co.,Ltd.,Haikou 570314, China and Qilu Pharmaceutical Co.,Ltd.,Haikou 570314, China |
| |
| Abstract: | Gefitinib is an EGFR inhibitor.It is only effective in cancers with mutated and overactive EGFR.The CFDA approved gefitinib in 2005 for non-small cell lung cancer(NSCLC).It was approved as monotherapy for the treatment of patients with locally advanced or metastatic NSCLC after failure of both platinum-based and docetaxel chemotherapies.On July 13,2015,FDA approved as a first-line treatment for NSCLC.The advancement of gefitinib in current clinic researches were reviewed in this article. |
| |
| Keywords: | Gefitinib Anticancer Clinical progress |
| 本文献已被 万方数据 等数据库收录！ |
| 点击此处可从《药学研究》浏览原始摘要信息 |
|
点击此处可从《药学研究》下载免费的PDF全文 |
|
